Roche joins obesity drug race with $2.7bn deal with Carmo

Roche has agreed to acquire unlisted obesity drug developer Carmot Therapeutics for a $2.7bn upfront payment, joining a list of rivals seeking to challenge dominant weight-loss drug makers Novo Nordisk and Eli Lilly.

Share This Post:

POPULAR POSTS
FOLLOW US
Like Us On Facebook
Follow Us On Twitter
Subscribe To Our Channel
TikTok
LIVE STREAM